Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
News Source : Financial Post
News Summary
- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) is a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases.
- SAT-3247 is an oral, small-molecule tablet designed to restore muscle regeneration by addressing deficits in muscle stem cell polarity.
- “2025 was a defining year for Satellos, and we are excited by the progress we have made across our clinical programs,” says CEO Frank Gleeson.
Satellos audited financial statements for the year ended Dec. 31, 2025 and 2024, and the related managements discussion and analysis (MD&A) will be available on the Company website and SEDAR+ at [+5604 chars]
Never miss a story from us, subscribe to our newsletter